Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other Non-Current Liabilities (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 22.73% to $1.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Dec 2025, down 22.73% year-over-year, with the annual reading at $1.7 million for FY2025, 22.73% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.7 million at Myriad Genetics, roughly flat from $1.7 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $48.1 million in Q4 2023, with the low at $1.7 million in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $21.9 million, with a median of $29.2 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities surged 780.43% in 2023, then plummeted 95.43% in 2024.
  • Over 5 years, Other Non-Current Liabilities stood at $32.1 million in 2021, then skyrocketed by 36.76% to $43.9 million in 2022, then grew by 9.57% to $48.1 million in 2023, then tumbled by 95.43% to $2.2 million in 2024, then dropped by 22.73% to $1.7 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.7 million, $1.7 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.